ESR1 and breast carcinoma: These results indicate that I3C maybe the major inhibitor of ERα signaling by the combination of LUT and I3C, and CUR may be the major contributor of TNBC inhibition by the combination of LUT and CUR, given that the anti-ER+ breast cancer effect of CUR was not mediated by the AhR-degraded ERα pathway [24].